peViva.com markets biomarkers for use in oncology, hepatology & research
About peViva.com
PEVIVA was established in 2000, having been granted exclusive rights to a unique apoptosis marker for cytokeratin 18 (CK18) expressing cells of epithelial origin. We strive to continuously acquire and develop novel intellectual property from the academic research and healthcare market for the detection and quantification of different forms of cell death in normal or pathophysiological circumstances.
